Janux Therapeutics
James has served as the General Counsel of Janux Therapeutics since July 2021, where he manages the legal aspects of corporate governance, public company and securities compliance, finance, employment, and complex commercial transactions. Prior to Janux, James had more than 17 years of experience as a corporate and securities lawyer with Cooley LLP, where his practice focused primarily on biotechnology companies. While at Cooley, James managed a wide range of financing, M&A and collaboration transactions.
James received a J.D., cum laude, from the University of San Diego School of Law, an LL.M. in Securities and Financial Regulation, with distinction, from Georgetown University Law Center, and a B.A. from the University of California, Los Angeles.
This person is not in any offices
Janux Therapeutics
1 followers
Janux Therapeutics is developing safe, effective novel immunotherapies with the company’s proprietary TRACTr technology. Janux’s TRACTr technology employs a modular design to rapidly engineer drug candidates against specific targets.